Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Kemp

Neurological Surgery Madison, WI Medical Doctor

NPI 1306251947 CMS profile 769548

309 W Johnson St, Madison, WI 53703

Open in the dashboard

General payments

$7,878

39 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Kemp of Madison, WI is reported in the CMS Open Payments database as having received $7,878 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,548 10
2024 General $599 5
2023 General $5,088 15
2022 General $529 7
2021 General $115 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Kemp
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to William Kemp were reported at $1,548. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year William Kemp Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $0 $294 $76–$2,174 $114
2021 $115 $387 $105–$2,432 $132
2022 $529 $542 $139–$2,989 $149
2023 $5,088 $534 $145–$2,697 $160
2024 $599 $574 $155–$3,046 $164
2025 $1,548 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alphatec Spine, Inc $4,746 8 payments
  2. Globus Medical, Inc. $1,380 7 payments
  3. Medtronic, Inc. $731 11 payments
  4. Stryker Corporation $603 7 payments
  5. Augmedics Inc. $250 3 payments
  6. Heron Therapeutics, Inc. $109 1 payment
  7. AbbVie, Inc. $33 1 payment
  8. Orthofix Medical, Inc. $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $4,918 7 payments
  2. Food and Beverage $2,960 32 payments
Products named General payments · program years 2021–2025
  1. Other - Miscellaneous $3,990 4 payments
  2. EXCELSIUS GPS $1,362 6 payments
  3. Xvision $1,250 15 payments
  4. MAZOR X SYSTEM $273 4 payments
  5. CAPRI CORPECTOMY CAGE SYSTEM $224 2 payments
  6. Invictus MIS $201 2 payments
  7. PIVOX Oblique Lateral Spinal System $167 2 payments
  8. N/A $166 2 payments
  9. OZARK CERVICAL PLATE SYSTEM $159 1 payment
  10. SERRATO $113 1 payment
  11. Other $585 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

176

Median for Neurosurgery: 83

Drug cost

$1,337

Median for Neurosurgery: $872

Branded share of claims

15.3%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 45 $291
Oxycodone Hcl Generic 19 $219
Naproxen Generic 34 $217
Methocarbamol Generic 22 $199
Gabapentin Generic 12 $140
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $113
Tizanidine Hcl Generic 17 $109
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 15 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$366,365

Of which drugs: $501

Medicare patients

339

Average age 72

Services billed

2,384

168 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Osteoporosis 31%
Ischemic heart disease 29%
Diabetes 24%
Depression 18%
Chronic kidney disease 13%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 60 $333
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 31 205 $163

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record